RTOG 0436: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer who are Treated without Surgery
Description of Research
The purpose of this study is to compare the effects, good and/or bad, of radiation therapy and chemotherapy with or without the addition of cetuximab to find out which treatment is better. Cetuximab may delay or prevent tumor growth by blocking certain cellular chemical pathways that lead to tumor development. Cetuximab is approved by the FDA for the treatment of colorectal and head and neck cancers. Cetuximab has not been approved as a treatment for patients with esophageal cancer and is considered investigational in this study.
Principal Investigator
Jedidiah Monson, M.D.
Inclusion/Notes
Histologic proof of primary squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction. Involvement of the GE junction with Siewert type I or II tumors. Stage T1N1M0; T2-4, Any N, M0; Any T, Any N, M1a
